Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-10-10

No results posted yet for this study

Summary

This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Conditions

Sponsors & Collaborators

  • QED Therapeutics, Inc., a Bridgebio company

    lead INDUSTRY

Eligibility

Min Age
30 Months
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-05
Primary Completion
2026-10-31
Completion
2026-10-31

Countries

  • United States
  • Australia
  • Canada
  • France
  • Norway
  • Portugal
  • Singapore
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06410976 on ClinicalTrials.gov